Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Technical considerations and the learning curve.
Melissa E HoggFrancisco IzquierdoOliver S EngKiran Kalyan TuragaPublished in: Journal of surgical oncology (2020)
Over the past decade, there has been a considerable increase in the utilization of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of patients with peritoneal metastases. This is due to improved safety and favorable oncologic outcomes, including curative potential. CRS/HIPEC has a steep learning curve and requires familiarity with peritonectomy procedures. This review will outline the technical aspects and learning curve of CRS/HIPEC.
Keyphrases
- minimally invasive
- coronary artery bypass
- locally advanced
- rectal cancer
- surgical site infection
- metastatic renal cell carcinoma
- squamous cell carcinoma
- robot assisted
- type diabetes
- metabolic syndrome
- radical prostatectomy
- percutaneous coronary intervention
- prognostic factors
- skeletal muscle
- adipose tissue
- risk assessment
- climate change
- atrial fibrillation
- insulin resistance
- coronary artery disease
- weight loss